Bronchial carcinoma after lung transplantation: A single-center experience

Yserbyt, Jonas; Verleden, Geert M.; Dupont, Lieven; Raemdonck, Dirk Van; Dooms, Christophe

doi:10.1016/j.healun.2012.02.022

Cited by 30 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of bronchogenic carcinoma in the transplanted lung ranged from 0.3% to 0.4% (39). This is lower than what was found in our own series from the Leuven Lung Transplant Group with a prevalence of 4/224 (1.8%) patients, all after doublelung transplantation for emphysema or fibrosis (53).…”

Section: Primary Lung Cancer In the Allograftcontrasting

confidence: 57%

“…The median survival after diagnosis was only 10±7 months, with a significant survival difference between patients with limited versus extensive disease (P=0.037). The latter had a median survival of only 6 months compared with 21 months for patients with limited stages of bronchial carcinoma (53). Based on the nice review by Olland et al and our further literature search, 19 papers (31,32,52-68) have described primary lung cancer in the native lung after single-lung transplantation.…”

Section: Primary Lung Cancer In the Remaining Native Lung After Singlmentioning

confidence: 97%

“…Referring to the study by Olland et al and our own literature search, 12 references (31,47,53,61,63,(66)(67)(68)(69)(70)(71)(72) were found reporting on primary lung cancer developing in the transplanted lung, most often after double-lung transplantation. The prevalence of bronchogenic carcinoma in the transplanted lung ranged from 0.3% to 0.4% (39).…”

Section: Primary Lung Cancer In the Allograftmentioning

confidence: 99%

See 2 more Smart Citations

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Raemdonck¹,

Vos²,

Yserbyt³

et al. 2016

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

Lung transplantation is an effective and safe therapy for carefully selected patients suffering from a variety of end-stage pulmonary diseases. Lung cancer negatively affects prognosis, particularly in patients who are no longer candidates for complete resection. Lung transplantation can be considered for carefully selected and well staged lung cancer patients with proven, lung-limited, multifocal, (minimally invasive) adenocarcinoma in situ (AIS) (previously called bronchioloalveolar cell carcinoma) causing respiratory failure. Despite a substantial risk of tumour recurrence (33-75%), lung transplantation may offer a survival benefit (50% at 5 years) with best palliation of their disease. Reports on lung transplantation for other low-grade malignancies are rare. Lung transplant candidates at higher risk for developing lung cancer [mainly previous smokers with chronic obstructive lung disease (COPD) and idiopathic pulmonary fibrosis (IPF) or older patients] should be thoroughly and repeatedly screened for lung cancer prior to listing, and preferably also during waiting list time if longer than 1 year, including the use of PET-CT scan and EBUS-assisted bronchoscopy in case of undefined, but suspicious pulmonary abnormalities. Double-lung transplantation should now replace single-lung transplantation in these high-risk patients because of a 6-9% prevalence of lung cancer developing in the remaining native lung. Patients with unexpected, early stage bronchial carcinoma in the explanted lung may have favourable survival without recurrence. Early PET-CT (at 3-6 months) following lung transplantation is advisable to detect early, subclinical disease progression. Donor lungs from (former) smokers should be well examined at retrieval. Suspicious nodules should be biopsied to avoid grafting cancer in the recipient. Close follow-up with regular visits and screening test in all recipients is needed because of the increased risk of developing a primary or secondary cancer in the allograft from either donor or recipient origin.

show abstract

Section: Primary Lung Cancer In the Allograftcontrasting

confidence: 57%

Section: Primary Lung Cancer In the Remaining Native Lung After Singlmentioning

confidence: 97%

Section: Primary Lung Cancer In the Allograftmentioning

confidence: 99%

See 1 more Smart Citation

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Raemdonck¹,

Vos²,

Yserbyt³

et al. 2016

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The disease in the native lung (emphysema, PF) certainly plays an important role as remarked by the different incidence in the native and transplanted lung (5). The mean age of these patients is around 60 years (6). Age and a history of smoking are independent risk factors; however, they appear to be less powerful when compared to SLT that greatly increases the risk (7); our patient never smoked.…”

Section: Discussionmentioning

confidence: 86%

Devastating fast-growing lung cancer after single lung transplantation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All cases were nonsmall cell lung cancer. 1,3,12 The 2 cases of lung cancer in the native lung occurred in COPD patients that underwent single LT. The occurrence of this type of cancer is in relation with the elevated prevalence of COPD and IPF patients as LT recipients, diseases that are independent risk factors for cancer and that share common occupational and environmental risk factors.…”

Section: Lung Cancermentioning

confidence: 99%

Malignancies following lung transplantation: the Portuguese experience

Caldeira¹,

Silva²,

Caires³

et al. 2019

JCPCR

View full text Add to dashboard Cite

Malignancy is an important complication after lung transplantation (LT), which is related to common risk factors in these patients, oncogenic viruses and immunosuppression therapy (IST). We retrospectively analyzed all cases of malignancy in the 182 patients that underwent LT between June 2001 and December 2017 in Portugal. We noticed an incidence of 7.6%, similar to that described in the literature, with a mean age of 53 years and a mean time after LT of 25 months. As in other series, the most common types of cancer were skin cancer (2.7%), post transplant lymphoproliferative disorders (2.2%) and lung cancer (1.6%). Unexpectedly we found an important incidence of gastric cancer (1,1%) not previously described in the literature that we relate to the elevated incidence of this cancer in our country. All patients underwent treatment and IST adjustments, according to a multidisciplinary team approach. In this series, 4 patients died due to cancer (33.3%) with a median survival of 26 months. We conclude that cancer is an important complication after LT and further investigation and awareness is needed to optimize diagnosis and management of this condition.

show abstract

Bronchial carcinoma after lung transplantation: A single-center experience

Cited by 30 publications

References 15 publications

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Devastating fast-growing lung cancer after single lung transplantation

Malignancies following lung transplantation: the Portuguese experience

Contact Info

Product

Resources

About